Skip to main content
Fig. 6 | Journal of Biomedical Science

Fig. 6

From: Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling

Fig. 6

CXCL1 and CXCL2 promotes SOR resistance by activating the CXCR2/ERK pathway. A HepG2 cells were treated with CM and SOR (10 μM) for 48 h. Cell lysates were collected and subjected to Western blotting with the indicated antibodies. G: HepG2 monoculture CM, GU: HepG2/U937 coculture CM, GTCM: HepG2/TAMCM coculture CM, GTCyto: HepG2/ M2 MφsCyto coculture CM. B HepG2 cells were treated with indicated CM, SB225002 (50 μM), and SOR (10 μM) for 48 h. Cell lysates were collected and subjected to Western blotting with the indicated antibodies. C HepG2 cells, Hep3B cells, and Huh7 cells were treated with CXCL1 or CXCL2 in combination with PD0325901 (10 μM) and SOR (10 μM for HepG2, 15 μM for Hep3B, 5 μM for Huh7) for 48 h. The bar graphs depict the percentages of apoptotic cells measured by flow cytometry with double staining for Annexin V and PI. ***P < 0.001 vs. untreated cells. D HepG2 cells, Hep3B cells, and Huh7 cells were treated with CXCL1 or CXCL2 in combination with PD0325901 (10 μM) for 24 h. The bar graphs depict the percentages of CD44+/CD133+ cells measured by flow cytometry with double staining for CD44 and CD133. ***P < 0.001 vs. untreated cells

Back to article page